Aerovate Therapeutics, Inc. (AVTE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVTE Stock Price Chart Interactive Chart >
AVTE Price/Volume Stats
| Current price | $12.71 | 52-week high | $29.43 |
| Prev. close | $12.37 | 52-week low | $7.74 |
| Day low | $12.31 | Volume | 42,600 |
| Day high | $13.03 | Avg. volume | 54,139 |
| 50-day MA | $14.35 | Dividend yield | N/A |
| 200-day MA | $13.77 | Market Cap | 310.25M |
Aerovate Therapeutics, Inc. (AVTE) Company Bio
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest AVTE News From Around the Web
Below are the latest news stories about Aerovate Therapeutics Inc that investors may wish to consider to help them evaluate AVTE as an investment opportunity.
Wedbush Thinks Aerovate Therapeutics’ Stock is Going to RecoverWedbush analyst Liana Moussatos reiterated a Buy rating on Aerovate Therapeutics (AVTE – Research Report) today and set a price target of $23.00. The company's shares closed last Friday at $9.46, close to its 52-week low of $9.02. According to TipRanks.com, Moussatos is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.0% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. Aerovate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.50. |
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial HypertensionWALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced the initiation of its I nhaled I m atinib P ulmonary A rterial H ypertension C linical T rial (IMPAHCT) Phase 2b/Phase 3 trial to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in adult patients with Pulmonary Arterial Hypertension (PAH). |
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA CapitalIn this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […] |
Aerovate Therapeutics (NASDAQ:AVTE) Earns Buy Rating from WedbushWedbush restated their buy rating on shares of Aerovate Therapeutics (NASDAQ:AVTE) in a research report sent to investors on Tuesday, Price Targets.com reports. They currently have a $22.00 price objective on the stock. A number of other brokerages also recently weighed in on AVTE. Zacks Investment Research raised shares of Aerovate Therapeutics from a sell [] |
Aerovate Therapeutics (NASDAQ:AVTE) Posts Earnings Results, Hits ExpectationsAerovate Therapeutics (NASDAQ:AVTE) released its quarterly earnings data on Sunday. The company reported ($0.26) EPS for the quarter, meeting analysts consensus estimates of ($0.26), MarketWatch Earnings reports. NASDAQ AVTE traded down $3.46 during trading hours on Tuesday, hitting $14.00. 6,115 shares of the company traded hands, compared to its average volume of 128,259. The stock [] |
AVTE Price Returns
| 1-mo | -8.76% |
| 3-mo | 33.79% |
| 6-mo | -7.50% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 7.80% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...